Peest D, Schmoll H J, Schedel I, Deicher H, Boll J, Essers U, Gamm H, Glück S, Görg K, Gramatzki M
Onkologie. 1986 Jun;9(3):168-9. doi: 10.1159/000215999.
257 untreated myeloma patients (stage II and III) were studied in a multicenter trial. The patients were randomized and received MP or VCMP therapy. No differences in remission rate could be found in both therapy arms. After successful remission induction those patients without maintenance therapy relapsed significantly earlier than those patients receiving maintenance therapy. In pilot studies an etoposide therapy was found ineffective and a multidrug therapy (VBAMDex) could induce high remission rates in high risk and pretreated patients.
